Cell Therapies & Oncolytic Virus Market By Application (Prostate cancer, Ovarian Cancer, Others) By Drug Class (Onxy-15, Reolysin, Others) Regional Analysis & Forecast - 2026

  • OI-78
  • |
  • Published date: Mar, 2019
  • |
  • Life Sciences & Healthcare
  • |
  • Pages

Oncolytic virus is considered as a genetically engineered or naturally occurring virus that will kill the cancer cells without harming the normal human tissues. Oncolytic Virus therapy is known to be a new therapeutic approach used for treating cancer and is showing promising results globally. With the advancements made in oncology and the virology, there are possible routes towards the engineering of viruses showing increased tumor selectivity and increased oncolytic activity. We will see progress in terms of viral delivery in the next few years, particularly in using the immune cell carriers that yet have to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combining viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies probably will be tested in early phase clinical trials. 

Market Overview

Global Oncolytic virus therapy market value is regarded for USD xx billion in 2017, and is known to grow at a CAGR of 19.32% to reach USD xx billion by 2025. Currently 2 oncolytic virus therapies are commercially available in the market. Most of the oncolytic virus therapies in clinical trials are in the preclinical phase followed by Phase-I trials. Amgen Inc. markets Imlygic, an oncolytic virus immunotherapy drug, but however several other competitors are expected to enter into the oncolytic virus immunotherapy in the forecast period.

Rising occurrence of more cancer cases and increasing cancer treating therapies development such as oncolytic virus are going to drive the growth of the market globally. Technological developments including natural killer cells and using combination therapies are also driving the global market growth. Additionally, ongoing development of virus therapies globally that are in the pipeline are going to enhance the oncolytic virus therapy market growth in the forecast period. An opccurrence of Immune reaction to the virus-based therapies caused by repeated administration of therapeutics to treat cancer is a key restraint that is hampering the market growth. High cost related to oncolytic virus therapy further affects market growth, especially in developing countries.

Key Developments

  • The only FDA-approved oncolytic virus present is talimogene laherparepvec (T-VEC; Imlygic), which is a form of herpes simplex virus type 1 (HSV-1) that is genetically modified in order to express granulocyte-macrophage-colony-stimulating factor.

  • In February 2018, Merck agreed to pay $394 million to acquire Viralytics, an Australian company developing Cavatak (CVA21), which is a formulation of coxsackievirus type A21. It is being studied in combination with pembrolizumab (Keytruda), a PD-1 inhibitor that Merck developed, in melanoma, prostate, lung, and bladder cancers.


Global Oncolytic Virus Therapy Market is segmented accordingly by application type, by drug class, and therapy type.

By application: The global market is segmented in to Prostate cancer, Ovarian Cancer, Melanoma, Breast Cancer and others. Melanoma is accounted for the largest share because most of the cancer therapies are developed for Melanoma cancers. Increasing prostate cancer cases are also leading to the strong growth rate in prostate cancer therapies in recent years.

By Drug class: The global market is segmented in to Onxy-15, Reolysin, Talimogene laherparepvec, RIGVIR. Talimogene laherparepvec is considered as the largest drug class that accounted for a major share in the market, and is due to its vast penetration in treating cancer.

By type: The global market is classified into Newcastle disease virus-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, adenoviruses-based oncolytic viruses, and HSV-based oncolytic viruses.

By Geography: The global market is segmented in to North America, South America, Europe, Asia Pacific and rest of the World. North America is leading the market globally and is due to increasing cancer cases that are associated with hectic lifestyles. Further, well-developed healthcare infrastructure is supported to the growth in this region.

Some of the key players of the global oncolytic virus therapy market include Cold Genesys, Vyriad, TILT Biotherapeutics, Genelux Corporation, Sorrento Therapeutics, Lokon Pharma, SillaJen Biotherapeutics, and PsiOxus Therapeutics. Regional and local players are known to offer specific application products to end-users.

Report Description: The report covers in-depth analysis on Cell Therapies & Oncolytic Virus Market. The report assesses the Cell Therapies & Oncolytic Virus related products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Prostate cancer, Ovarian Cancer, Melanoma, Breast Cancer and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.

The report includes in-depth company profiles of key players in Cell Therapies & Oncolytic Virus Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.

The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Cell Therapies & Oncolytic Virus

  • Provides a comparative analysis of key marketed products and pipeline

  • Provides key information on players involved on the Cell Therapies & Oncolytic Virus

  • Provides a complete overview of market segments and the regional outlook of Cell Therapies & Oncolytic Virus

  • Provides in-depth coverage of key news related toCell Therapies & Oncolytic Virus Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:

  • Data Collation (Primary & Secondary)

  • In-house Estimation (Based on proprietary databases and Models)

  • Market Triangulation

  • Forecasting

  • Market-related information is assembled from both primary and secondary sources. 

  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 

  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 

  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 



Choose Licence Type

Credit card Logo
Inquiry Before Buying

Related Reports

Contact Us

Email Us at: | Reach Us at: +91 966 6620 365 | +1 857 444 9369 (US)  tick-under  tick-under